In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions
Journal of Antimicrobial Chemotherapy · 03.09.2024 · 79 (9) · 2221-2226
DOI: 10.1093/jac/dkae217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 08.07.2024. Verfasst von Alexandra David und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health, Faculty of Population Health, University College London, London, UK. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Microbial Sensitivity Tests, DNA Topoisomerase IV, Acenaphthenes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Örebro County Council Research Committee, UCL-Birkbeck Medical Research Council Doctoral Training Programme, UK, NIH HHS.
Abstract (Originalsprache)
Objectives
The novel dual-target triazaacenaphthylene, gepotidacin, recently showed promising results in its Phase III randomized controlled trial for the treatment of gonorrhoea. We investigated alterations in the gepotidacin GyrA and ParC targets in gonococci by in silico mining of publicly available global genomes (n = 33 213) and determined gepotidacin MICs in isolates with GyrA A92 alterations combined with other GyrA and/or ParC alterations.
Methods
We examined gonococcal gyrA and parC alleles available at the European Nucleotide Archive. MICs were determined using the agar dilution method (gepotidacin) or Etest (four antimicrobials). Models of DNA gyrase and topoisomerase IV were obtained from AlphaFold and used to model gepotidacin in the binding site.
Results
GyrA A92 alterations were identified in 0.24% of genomes: GyrA A92P/S/V + S91F + D95Y/A/N (0.208%), A92P + S91F (0.024%) and A92P (0.003%), but no A92T (previously associated with gepotidacin resistance) was found. ParC D86 alterations were found in 10.6% of genomes: ParC D86N/G (10.5%), D86N + S87I (0.051%), D86N + S88P (0.012%) and D86G + E91G (0.003%). One isolate had GyrA A92P + ParC D86N alterations, but remained susceptible to gepotidacin (MIC = 0.125 mg/L). No GyrA plus ParC alterations resulted in a gepotidacin MIC > 4 mg/L. Modelling of gepotidacin binding to GyrA A92/A92T/A92P suggested that gepotidacin resistance due to GyrA A92T might be linked to the formation of a new polar contact with DNA.
Conclusions
In silico mining of 33 213 global gonococcal genomes (isolates from 1928 to 2023) showed that A92 is highly conserved in GyrA, while alterations in D86 of ParC are common. No GyrA plus ParC alterations caused gepotidacin resistance. MIC determination and genomic surveillance of potential antimicrobial resistance determinants are imperative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Global Health, Faculty of Population Health, University College London, London, UK.
- WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Biochemistry and Molecular Biology, University of South Alabama, AL, USA.
- Hanoi Medical University, National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
- Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
ORCID-Profile: Magnus Unemo
Förderung
- Örebro County Council Research Committee
- UCL-Birkbeck Medical Research Council Doctoral Training Programme, UK
- NIH HHS
- NIAID NIH HHS
- Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden
- National Institutes of Health
Zitieren
APA
David, A., Golparian, D., Jacobsson, S., Stratton, C., Lan, P. T., Shimuta, K., Sonnenberg, P., Field, N., Ohnishi, M., Davies, C., & Unemo, M. (2024). In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions. Journal of Antimicrobial Chemotherapy, 79(9), 2221-2226. https://doi.org/10.1093/jac/dkae217
Vancouver
David A, Golparian D, Jacobsson S, Stratton C, Lan PT, Shimuta K, et al. In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions. Journal of Antimicrobial Chemotherapy. 2024;79(9):2221-2226. doi:10.1093/jac/dkae217
BibTeX
@article{David2024,
author = {David, Alexandra and Golparian, Daniel and Jacobsson, Susanne and Stratton, Caleb and Lan, Pham Thi and Shimuta, Ken and Sonnenberg, Pam and Field, Nigel and Ohnishi, Makoto and Davies, Christopher and Unemo, Magnus},
title = {In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {9},
pages = {2221--2226},
doi = {10.1093/jac/dkae217}
}
EUVIMED